among Canadians with AS has not previously been examined, using data from a large clinical registry. Objectives: To estimate the prevalence of EAMs, including uveitis, inflammatory bowel disease (IBD), dactylitis, and enthesitis, in a population of Canadians undergoing active management for AS. Methods: This retrospective study used RHUMADATA ® , a multicentre registry developed by rheumatologists of the IRRM and Centre d'ostéoporose et de rhumatologie de Québec to evaluate the effectiveness and safety of rheumatologic therapies. Up to 15 years of real-world observational data on the broad set of patients treated in clinical practice are available. The proportion with EAMs was estimated according to type. The frequency of EAMs was compared according to age at cohort entry (≤40 vs >40 years), sex, AS severity (by BASDAI score), and status of treatment with anti-TNFs (anti-TNF-naive, anti-TNF treated [without switching], and anti-TNF treated [with switching]). Results: The mean (SD) age at cohort entry was 36.0 (12.6) years, and 60.0% were male. Of the 944 patients, 268 (28.4%) were ever diagnosed with an EAM over a median of 9.66 (10.58) years of follow-up. Prevalence was 14.7% for uveitis, 5.8% for IBD, 4.3% for dactylitis, and 9.0% for enthesitis (Table) 
Conclusions: EAMs are common among Canadians with AS, occurring in up to 28% over almost 10 years of follow-up, with uveitis occurring the most frequently (in almost 15% of the cohort). EAMs were most frequent among those with more severe disease (in 34%) and among those treated with anti-TNFs (in 20-50% of such patients). These estimates are useful for comparing to other geographic areas, where the risk factor distribution for AS and its sequelae would differ; and for use in economic models to evaluate the benefits and costs of new therapies. Background: Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease predominantly affecting the sacroiliac joints and spine. Ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) have been considered to represent the same axial spondyloarthritis disorder, but are differentiated by the presence or absence of structural changes in the sacroiliac joints as determined by common imaging modalities. Objectives: To better understand the symptoms and clinical characteristics of nr-axSpA patients and how they compare to ankylosing spondylitis patients in Europe. Methods: Data drom the 2015 SpA Disease Specific Programme, a crosssectional, multi-national survey of patients and rheumatologists conducted in France, Germany, Italy, Spain, and the UNited Kingdom were analyzed. Rheumatologists (n=299) completed forms containing patient demographics, clinical results and symptomology. Symptoms, disease activity, and disease status (defined as improving, stable, unstable, deteriorating) of AS and nr-axSpA patients were compared. Results: A total of 3,033 patients (AS: 1,520; nr-axSpA: 1,513) were included in the analysis. A higher proportion of AS patients were male (72% vs. 53%), older (mean age=44.8 vs. 41.0), had a higher BMI and were employed when compared to nr-axSpA patients. Nr-axSpA patients' current disease status was less likely to be stable (p<0.0001) in comparison to AS patients. Nr-axSpA patients were also less likely to be in remission (p<0.0001). Nr-axSpA patients were reported as having higher pain level (p=0.0333) than AS patients. AS patients had more axSpA symptoms, such as spinal fusion and loss of movement, however nr-axSpA patients were more likely to have inflammatory back pain, enthesitis, persistent lower back pain, and nocturnal wakening. Conclusions: Both nr-axSpA and AS appear to have many similar clinical characteristics with few distinct features between them. However, in spite of these similarities, nr-axSpA patients show less stability and a lower likelihood of remission when compared to AS patients. These findings may suggest that nr-axSpA is as burdensome as AS, and that both conditions may warrant similar treatment approaches from an early stage. 
